Updates are available Correction dated 2022-04-15

Article History

Received: 10 August 2021

Accepted: 10 December 2021

First Online: 28 January 2022

Change Date: 15 April 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1245/s10434-022-11622-0

Disclosure

: RAS has received fees for professional services from Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. DEG Advisory boards—Amgen, Bayer, Q Biotics; Speaker Fee—BMS. RPMS has received honoraria for advisory board participation from MSD, Novartis, and Qbiotics and speaking honoraria from BMS and Novartis. GVL is consultant advisor for Aduro Biotech Inc, Amgen Inc, Array Biopharma Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Evaxion Biotech A/S, Hexel AG, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals Inc., SkylineDX B.V., Specialised Therapeutics Australia Pty Ltd. ROB has received institutional research grants from Bristol-Myers Squibb (BMS) and SkyLineDx, speaker honoraria from Roche and Pfizer, and has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme. MCL has received honoraria for advisory board participation from BMS. JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, travel support from GSK and Provectus Inc, and support for conference attendance from Novartis. GCK PI of Investigator Initiated Trial (IIT) sponsored by Merck. AAET travel support for meetings from Agenus. PR has received honoraria for lectures and Advisory Boards from Novartis, MSD, BMS, Roche, Bayer, Pierre Fabre, Sanofi, Merck, Blueprint Medicines. PAA has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Array, Merck Serono, Pierre-Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore, Seagen, iTeos. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Array, Sanofi and travel support from MSD. TJH Research funding (to her institution) from Genentech, SkylineDX. JPDN Speaker for BMS and MSD. JSZ Relevant to the work are advisory board for Merck, Novartis. MSB Institutional research support from Genentech (related to this work) and from Bristol-Myers Squibb, Immune Design, Pharmacyclics, Marker Therapeutics, Sorrento Therapeutics, Transgene, Viewpoint Molecular Targeting, and Merck (unrelated to this work). Unpaid consultant for Sorrento Therapeutics, Viewpoint Molecular Targeting, and TILT Biotherapeutics. MTT Past advisory board relationships with Myriad Genetics, Nanostring, Bristol Meyers and Seattle Genetics (all closed); currently performing central pathology review for a Merck sponsored trial. AMM Advisory Boards—BMS, MSD, Novartis, Roche, Pierre-Fabre, Qbiotics. MBF Advisory boards—BMS, Novartis, Merck, Sanofi, Nektar, Pulse Bioscience. HT has received consulting fees from Merck, BMS, Novartis, Genentech, Eisai, Iovance, Karyopharm and Boxer Capital, and research funding to institution from Merck, BMS, Novartis, Genentech, GSK. CUB Advisory role: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures. GMB: Sponsored Research Agreement, Olink Proteomics, Palleon Pharmaceuticals, InterVenn Biosciences; Scientific Advisory Board: Nektar Therapeutics, Novartis, Ankyra; Consulting: InterVenn, Merck. VKS: Dr. Sondak is a compensated consultant for Bristol Myers Squibb, Eisai, Merck, Novartis, Regeneron, and Replimune and receives research funding from Neogene Therapeutics. All other authors declare no conflicts of interest.